ALIDYA DISTRIBUTION in FRANCE | FRANCE-HEALTH

ALIDYA

THE FIRST INJECTABLE DEVICE particularly suitable for the prevention and treatment of gynoid lipodystrophy (cellulite). ALIDYA is the first injectable device specifically indicated for the prevention and treatment of gynoid lipodystrophy (cellulite). Originating from studies conducted by Prof. Pasquale Motolese, which identified as a contributory factor in the genesis of cellulite, the presence of extracellular toxic ions, deposited following alterations of the vascular microcirculation. The action of ALIDYA is expressed by the solubilization, and as a consequence of the removal of these extracellular toxic elements, as well as the restoration of normal cell omeostasis, translates clinically in the improvement of the area affected or predisposed to the development of cellulite.

ACTION

The action of ALIDYA is expressed by the solubilization, and as a consequence of the removal of these extracellular toxic elements, as well as the restoration of normal cell omeostasis, translates clinically in the improvement of the area affected or predisposed to the development of cellulite.

PACKAGING

The product is provided in a package with 5 vials, each containing 340 mg of powder and 5 vials with 10 ml of solvent.

USE

CE marked injectable device formulated by Prof. P. Motolese. ALIDYA must be injected using the mesotherapy technique in the area affected with gnnoid lipodystrophy “cellulite” in weekly sessions. The ALIDYA treatment requires a minimum average of 7 applications in the specific area to be treated, up to a maximum of 12 treatments. They are to be applied on a weekly basis, using 1-2 vials per session, depending upon the extent of the area to be treated.

COMPOSITION

  • A polyamino acid gel
  • D-(+) Alpha-D-glucopyranose
  • 1-4 glucosidico
  • Sodium ethylenediaminetetraacetic
  • Amino acid buffer system with sodium bicarbonate corrector
  • Osmolarity regulator

ITS FORMULA IS DESIGNED TO

  • solubilize and remove toxic extracellular elements secondary to vascular damage of the microcirculation
  • alkalize the extracellular matrix
  • improve the oxygenation to the tissues
  • provide the biological components for the restructuring the extracellular matrix
  • normalize the physiological function of the adipose tissue
  • ALIDYA is the result of the most recent research on the physiopathology called gynoid lipodystrophy.

Marllor Biomedical Srl Via Torconca, 1 47842 S. Giovanni in Marignano (RN)

ALIDYA Anti LipoDystrophic Agents
€87.50 (tax excl.)
(tax excl.)
THE FIRST INJECTABLE DEVICE. REMOVES CELLULITE AND BRINGS MAINTAINING RESULTS. PRODUCT FOR MEDICAL USE ONLY. Particularly indicated for prevention and the treatment of gynoid lipodystrophy (cellulitis). First registered medicinal product for cellulite treatment. (5X340mg vials with powder + 5X10ml vials with solvent).